Adimab Announces Multi-Target Expansion for the Discovery of Antibodies with Another Global Pharma Partner

May 8, 2019 Off By BusinessWire

LEBANON, N.H.–(BUSINESS WIRE)–Adimab,
LLC
, the global leader in the discovery and optimization of fully
human monoclonal and bispecific antibodies, announced the expansion of
an earlier partnership with Novartis. Adimab will use its proprietary
platform to discover and optimize antibodies against nine targets chosen
by Novartis, who will have the rights to develop and commercialize
therapeutic programs resulting from the collaboration.

“Adimab continues to build on its reputation as an innovation powerhouse
and the premier provider for therapeutic antibody discovery and
engineering,” said Guy Van Meter, Chief Business Officer at Adimab. “Our
goal for every partnership is to impress the partner and expand the
collaboration. The best way to do that is to deliver the highest quality
therapeutic molecules possible, and to date, more than 80% of our
partnerships have expanded.”

Under the terms of the agreement, Adimab will use its proprietary
discovery and engineering platform to generate fully human antibodies
for development as therapeutic products for nine targets chosen by
Novartis. Novartis will retain worldwide commercial rights to these
therapeutic antibodies, for which Adimab would receive upfront payment,
research support, milestones and royalties on product sales.

This is the second expansion of the Adimab-Novartis partnership.
Adimab’s initial partnership with Novartis was signed in June 2010, and
was first expanded in October 2017.

About Adimab

Adimab is the leading technology provider for antibody-based drug
discovery, focusing solely on its partners without pursuing an internal
product pipeline. Since 2009, Adimab has partnered with 65
pharmaceutical and biotechnology companies, generating more than 280
therapeutic programs. The Adimab technology has been transferred and
implemented at Biogen, GSK, Lilly, Merck, and Novo Nordisk. Funded
discovery partners include leading pharmaceutical companies, such as
Boehringer Ingelheim, Celgene, Genentech, Gilead, Kyowa Hakko Kirin,
Roche, Sanofi, Takeda and others. Adimab has also partnered with many
early-stage venture-backed companies, including Alector, Cullinan
Oncology, Dragonfly, Pliant, Potenza, Tizona, iTeos and others, as well
as mid-size public biopharmaceutical companies such as Acceleron, Five
Prime, Innovent, Jounce, Mersana, Scholar Rock, Seattle Genetics,
Surface Oncology, and others.

Adimab’s integrated antibody discovery and engineering platform provides
unprecedented speed from antigen to purified, full-length human IgGs.
Adimab offers fundamental advantages by delivering diverse panels of
therapeutically relevant antibodies that meet the most aggressive
standards for affinity, epitope coverage, species cross-reactivity, and
developability. Adimab enables its partners to rapidly expand their
biologics pipelines through a broad spectrum of technology access
arrangements. For more information, visit http://www.adimab.com.

Contacts

Guy Van Meter
Chief Business Officer
Adimab, LLC.
(603)
653-5775